The multiplex molecular diagnostics market has anticipated a CAGR of 5.4% during the forecast period, up from US$ 23.2 Billion in 2022 to reach the valuation of US$ 39.25 Billion by 2032.
| Attributes | Details |
|---|---|
| Multiplex Molecular Diagnostic (CAGR) | 5.4% |
| Multiplex Molecular Diagnostic (2022) | US$ 23.2 Billion |
| Multiplex Molecular Diagnostic (2032) | US$ 39.25 Billion |
The demand for multiplex molecular diagnostics is anticipated to increase at a decent rate in the forecast period. An increase in economic stability leads to improve funding in healthcare and research, which leads to an increase in sales of multiplex molecular diagnostics.
An increase in the incidence of gastrointestinal, respiratory and CNS infections has led to the growth of the multiplex molecular diagnostics market. That’s why there is a huge demand for multiplex molecular diagnostics.
As the clinical symptoms of these diseases are not pathogen-specific, therefore its differential diagnosis is broad. Previously, for performing microbiologic diagnosis, one needed a combination of antigen tests, microscopy, culture, and pathogen-specific PCR assays.
Due to this, there is a widespread use of and demand for multiplex molecular diagnostics in healthcare centres.
As the multiplex molecular diagnostic approach came into practice, it simplified testing algorithms and laboratory workflow, which led to an increase in sales of multiplex molecular diagnostics.
Multiplex molecular diagnostics have significantly increased the diagnostic yield with the launch of multiplex PCRs; the tests have become more sensitive than the routine culture or antigen detection. This leads to generating sales of multiplex molecular diagnostics in the multiplex molecular diagnostics market.
Still, there are a few limitations to the current multiplex molecular diagnostics test. In its current form, multiplex molecular diagnostics cannot detect all potential pathogens, which can decline the sales of multiplex molecular diagnostics.
Besides, a negative panel result doesn’t on entirely exclude infection. Further, with panel-based methodology, current platforms offer few or limited options to select which organism targets needs to be tested. Due to this, the demand for multiplex molecular diagnostics can decrease in the marketplace.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Several industries are the key contributors to the multiplex molecular diagnostic market. Some of them are clinical research, laboratory, hospitals, academic & research centres and others.
The multiplex molecular diagnostic is used to detect infections such as tuberculosis, chlamydia, H1N1 virus and other diseases. Due to identifying such diseases, there is likely to increase in demand for multiplex molecular diagnostics by the end users.
These industries are likely to grow the multiplex molecular diagnosis market share along with sales of multiplex molecular diagnostics in the coming forecast period.
North America is anticipated to be the dominant revenue-generating region for the immunoaffinity columns multiplex molecular diagnostics market over the forecasting period. Demand for multiplex molecular diagnostics is likely to grow higher in this region as compared to others.
Many factors like well-developed high-tech diagnostic labs, the presence of a large number of key players, and favourable research funding are contributing to the high revenue generation in this region for multiplex molecular diagnostics market share.
After North America, Europe is anticipated to be the second most important region for the multiplex molecular diagnostics market share. This is attributed to the increased number of patient care and epidemiologic studies being conducted in this region.
The Asia Pacific regional multiplex molecular diagnostics market share is expected to grow at the fastest rate due to factors such as the rising adoption of advanced diagnostic technologies and the high prevalence of infectious diseases. This leads to an increase in sales of multiplex molecular diagnostics in the region.
The Middle East and Africa are expected to be the least lucrative region in the immunoaffinity columns multiplex molecular diagnostics market due to the lack of awareness about modern diagnostic techniques and the lack of advanced clinical laboratories.
Hence, there is expected to decline in the sales of multiplex molecular diagnostics in these regions.
Principal Consultant
Demand for multiplex molecular diagnostics is likely to increase in the manufacturing industries, which are playing a key role in the growth of the multiple molecular diagnostics market.
Some of the key players present in the multiplex molecular diagnostics market share include BD, bioMérieux SA, GenMark Diagnostics, Inc, Hologic, Luminex Corporation and many more. In addition, the presence of small and local manufacturers across the countries will account for competitiveness in the multiplex molecular diagnostics market.
These manufacturing companies are leading as key a player, which leads to an increase in the sales of multiplex molecular diagnostics in the forecast period.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.4% from 2022 to 2032 |
| Base year for estimation | 2022 |
| Historical data | 2015 – 2021 |
| Forecast period | 2023 – 2032 |
| Quantitative units | Revenue in USD billion and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | By Product, By Method, By End User & By Region |
| Regional scope | North America; Latin America; Europe; Middle East and; Africa (MEA); East Asia; South Asia; Oceania |
| Country scope | U.S., Canada, Mexico, Brazil, Argentina, Germany, Italy, France, U.K, Spain, Russia, India, Indonesia, Thailand, China, Japan, South Korea, Australia & New Zealand, GCC Countries, South Africa, North Africa |
| Key companies profiled | BD, bioMérieux SA, GenMark Diagnostics, Inc, Hologic, Luminex Corporation and many more |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The growth outlook for the multiplex molecular diagnostic market is predicted up to a CAGR of 5.4% during 2022-2032.
The North America region is expected to lead the multiplex molecular diagnostic market during forecast period.
The multiplex molecular diagnostic market is likely to hold the valuation of US$ 39.25 Billion by 2032.
Healthcare Industry is expected to be a key driver in the multiplex molecular diagnostic market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Component Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Component Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Component Type, 2022-2032 5.3.1. Systems 5.3.2. Test Kits 5.3.3. Reagents and Consumables 5.4. Y-o-Y Growth Trend Analysis By Component Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Component Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 6. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Indication, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Indication, 2022-2032 6.3.1. Respiratory Diseases 6.3.2. Gastrointestinal Diseases 6.3.3. CNS Infections 6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021 6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032 Deep-dive segmentation will be available in the sample on request 7. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals 7.3.2. Diagnostic Laboratories 7.3.3. Specialty Clinics 7.3.4. Academic and Research Institutes 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 Deep-dive segmentation will be available in the sample on request 8. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Component Type 9.2.3. By Indication 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Component Type 9.3.3. By Indication 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Component Type 10.2.3. By Indication 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Component Type 10.3.3. By Indication 10.3.4. By End User 10.4. Key Takeaways 11. Europe Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. U.K. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Component Type 11.2.3. By Indication 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Component Type 11.3.3. By Indication 11.3.4. By End User 11.4. Key Takeaways 12. East Asia Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Component Type 12.2.3. By Indication 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Component Type 12.3.3. By Indication 12.3.4. By End User 12.4. Key Takeaways 13. South Asia & Pacific Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Thailand 13.2.1.3. Indonesia 13.2.1.4. Malaysia 13.2.1.5. Singapore 13.2.1.6. Australia 13.2.1.7. New Zealand 13.2.1.8. Rest of South Asia & Pacific 13.2.2. By Component Type 13.2.3. By Indication 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Component Type 13.3.3. By Indication 13.3.4. By End User 13.4. Key Takeaways 14. MEA Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Component Type 14.2.3. By Indication 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Component Type 14.3.3. By Indication 14.3.4. By End User 14.4. Key Takeaways 15. Key Countries Multiplex Molecular Diagnostics Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Component Type 15.1.2.2. By Indication 15.1.2.3. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Component Type 15.2.2.2. By Indication 15.2.2.3. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Component Type 15.3.2.2. By Indication 15.3.2.3. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Component Type 15.4.2.2. By Indication 15.4.2.3. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Component Type 15.5.2.2. By Indication 15.5.2.3. By End User 15.6. U.K. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Component Type 15.6.2.2. By Indication 15.6.2.3. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Component Type 15.7.2.2. By Indication 15.7.2.3. By End User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Component Type 15.8.2.2. By Indication 15.8.2.3. By End User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Component Type 15.9.2.2. By Indication 15.9.2.3. By End User 15.10. China 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Component Type 15.10.2.2. By Indication 15.10.2.3. By End User 15.11. Japan 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Component Type 15.11.2.2. By Indication 15.11.2.3. By End User 15.12. South Korea 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Component Type 15.12.2.2. By Indication 15.12.2.3. By End User 15.13. India 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Component Type 15.13.2.2. By Indication 15.13.2.3. By End User 15.14. Thailand 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Component Type 15.14.2.2. By Indication 15.14.2.3. By End User 15.15. Indonesia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Component Type 15.15.2.2. By Indication 15.15.2.3. By End User 15.16. Malaysia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Component Type 15.16.2.2. By Indication 15.16.2.3. By End User 15.17. Singapore 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Component Type 15.17.2.2. By Indication 15.17.2.3. By End User 15.18. Australia 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Component Type 15.18.2.2. By Indication 15.18.2.3. By End User 15.19. New Zealand 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Component Type 15.19.2.2. By Indication 15.19.2.3. By End User 15.20. GCC Countries 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Component Type 15.20.2.2. By Indication 15.20.2.3. By End User 15.21. South Africa 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2021 15.21.2.1. By Component Type 15.21.2.2. By Indication 15.21.2.3. By End User 15.22. Israel 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2021 15.22.2.1. By Component Type 15.22.2.2. By Indication 15.22.2.3. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Component Type 16.3.3. By Indication 16.3.4. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Luminex Corporation 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. GenMark Diagnostics 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. BioFire Diagnostics, LLC 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. SiemensAG 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. BioMérieux 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Abbott Laboratories 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. EMPE Diagnostics AB 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. ELITechGroup 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. XCR Diagnostics 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Laboratory Corporation of America Holdings 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Multiplex Molecular Diagnostics Market
